SEC Comment Letter for NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Feb 8, 2019
NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Feb. 8, 2019 · CIK: 0000906709 · Accession: 0000000000-19-001648
AI Filing Summary & Sentiment
File numbers found in text: 000-24006
Letter
February 7, 2019 Gil M. Labrucherie Senior Vice President and Chief Financial Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Re:Nektar Therapeutics Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 1, 2018 File No. 000-24006 Dear Mr. Labrucherie: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 7, 2019
Gil M. Labrucherie
Senior Vice President and Chief Financial Officer
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158
Re:Nektar Therapeutics
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed March 1, 2018
File No. 000-24006
Dear Mr. Labrucherie:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance